The expression rate of CD38 in acute myeloid leukemia is high. It is reported that the expression of CD38 in myeloid leukemia is stable and can be used as a potential therapeutic target for leukemia. Daratumumab is a therapeutic drug targeting CD38. It is widely used in myeloma, but it has not been applied in AML. The prognosis of 4 patients with acute myeloid leukemia treated with CD38 monoclonal antibody combined with demethylating drugs / traditional chemotherapy was reviewed. Patient demographic data and clinical characteristics see table 1. One patient with de novo AML in the high-risk group achieved remission after Dara combined with azacytidine and venetoclax. The other three patients were suffering Relapsed/Refractory AML. Two of them achieved remission after Dara combined with azacytidine and venetoclax. The patient, who was non-remission after Dara combined with IA chemotherapy (Idarubicin, Cytosine Arabinoside), achieved remission after CART targeting CD38. In this paper, four cases were reported, and the rationality of CD38 targeted therapy was further analyzed.
No relevant conflicts of interest to declare.